Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
...
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, an...
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06577025
- Locations
- 🇪🇸
Hosp Clinico Univ de Salamanca, Salamanca, Spain
🇪🇸Hosp. Univ. Marques de Valdecilla, Santander, Spain
🇺🇸City of Hope, Duarte, California, United States
Exparel v Dexamethasone in RCR
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Rothman Institute Orthopaedics
- Target Recruit Count
- 126
- Registration Number
- NCT06575010
- Locations
- 🇺🇸
Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States
Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 20
- Registration Number
- NCT06574048
- Locations
- 🇺🇸
Nebraska Medicine, Hyperbaric Medicine Program, Clarkson Tower, Omaha, Nebraska, United States
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 318
- Registration Number
- NCT06561854
- Locations
- 🇫🇷
Service d'hématologie clinique et thérapie cellulaire, Saint-Antoine Hospital, Paris, France
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06554626
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT06550895
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06533748
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Dexamethasone Versus Demedetomidine Addition for Adductor Canal Block
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 90
- Registration Number
- NCT06527976
- Locations
- 🇪🇬
Assiut university, Assiut, Egypt
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Omar Nadeem, MD
- Target Recruit Count
- 49
- Registration Number
- NCT06518551
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06508983
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.